Similarly, KMT2B and TSC2 mutations, although not well‐studied in CRC, have been implicated in other malignancies for their roles in enhancing tumour aggression and stemness,7, 8 further supporting their inclusion as high‐risk markers in our model. The gene discussed is KMT2B; the disease is colorectal carcinoma.